Obicetrapib and APOE4: The First Oral Drug to Move Amyloid AND Tau

Obicetrapib is a next-generation oral CETP inhibitor — 10 mg once a day — being developed by NewAmsterdam Pharma [Masson et al., 2025]. CETP stands for cholesteryl ester transfer protein . Here it is in one sentence from a 2024 Current Atherosclerosis Reports review: CETP "tends to result in a net mass transfer of cholesteryl esters from HDL to VLDL and LDL, and a net mass transfer of triglycerides from VLDL to LDL and HDL" [Kastelein et al., 2024]. Translation: CETP is a shuttle that moves cholesterol out of your protective HDL particles and into your atherogenic LDL and VLDL particles. Block it, and two things happen at once: LDL drops and HDL climbs. Obicetrapib also potently raises ApoA-1 and ApoE — the apolipoproteins sitting on the surface of HDL particles [Kastelein et al., 2024]. Hold that ApoE piece. It is the key to why this drug matters specifically for APOE4 carriers. Mechanistically, obicetrapib works at a completely different spot on the cholesterol pathway than anything currently in the lipid toolkit: Statins block the liver from making cholesterol. Ezetimibe blocks gut absorption. PCSK9 inhibitors (evolocumab, alirocumab, inclisiran) increase hepatic LDL receptor recycling. Obicetrapib blocks the transfer step in the bloodstream itself. Different lever. Different target. Stacks on top of everything else. [link: APOE4 lipid management 101]

Why would a drug designed to shift blood lipids touch brain pathology? The mechanistic story is coherent and every step has independent support. APOE is a lipid-carrier protein. You have two copies of the APOE gene. The e4 variant produces a protein that traffics cholesterol less efficiently in the brain. Cerebral cholesterol moves on HDL-like particles that carry ApoE on their surface; those particles help clear beta-amyloid out of the small vessels of the brain (the cerebrovasculature where APOE4 carriers are especially vulnerable to cerebral amyloid angiopathy, or CAA). When you inhibit CETP — which is what obicetrapib does — you raise HDL particles and the ApoE riding on them [Kastelein et al., 2024]. From the 2025 mechanistic review in Journal of Cardiology and Cardiovascular Sciences : "In mice, genetic and pharmacological studies have shown that HDL levels are highly associated with CAA and that peripheral injection of synthetic HDL particles stimulates clearance of both Abeta42 and Abeta40 from the brain" [Poliakova & Wellington, 2025]. So the chain is: obicetrapib → more HDL particles carrying more ApoE → better cerebrovascular amyloid clearance → slower biomarker progression. Not a hand-wave. A pathway.

CETP inhibition has a body count. Three prior drugs died on the vine: Torcetrapib (Pfizer) — raised cardiovascular events and death; terminated 2006. Dalcetrapib (Roche) — futility. Evacetrapib (Lilly) — futility. Anacetrapib (Merck) — statistically positive but small effect; shelved after it was found to accumulate in adipose tissue. Torcetrapib is the cautionary tale that matters. From the 2024 review: torcetrapib "had structure-related off-target effects causing increased blood pressure, as well as increased aldosterone, steroid, and endothelin-1 levels, and electrolyte abnormalities" [Kastelein et al., 2024]. The CETP target wasn't the problem. The molecule was dirty. Obicetrapib was specifically engineered to avoid those off-target effects. From the BROOKLYN Phase 3 trial: "obicetrapib was observed to be well-tolerated, with safety results comparable to placebo and no increase in blood pressure. The treatment discontinuation rate for the obicetrapib arm was 7.6% versus 14.4% for placebo" [Nissen et al., 2025]. No BP signal. Lower dropouts than placebo. The 2025 meta-analysis of seven RCTs (n=3,381) confirmed: "there were no significant differences in adverse events" [Araujo et al., 2025]. Clean molecule. The target was never cursed — the old drugs were.

Here is my actual framework as an APOE4/4 carrier, a pharmacist, and the person building Phoenix. 1. Get your baseline now. If you don't have recent labs with an advanced lipid panel (ApoB, Lp(a), fasting insulin), get them. If you haven't had a plasma p-tau217 drawn, know it is now available as a commercial blood test. You want your starting number before any therapy decision. Phoenix's Bloodwork module tracks all of these against APOE4-specific reference ranges — because normal-for-population is not the same as optimal-for-APOE4 . 2. If you're already on max statin + ezetimibe + a PCSK9 inhibitor and still above ApoB/LDL goal — know that obicetrapib is the next wave. Talk to your lipidologist now. Ask where you sit relative to current 2024/2025 APOE4-appropriate targets (many of us should be aiming lower than standard guidelines). When the drug is approved, you want to be first in line. 3. If you're APOE4/4 and worried specifically about the AD trajectory — track PREVAIL. November 2026 readout. Positive CV outcomes → FDA filing → likely dedicated APOE4 prevention trial. That future trial will need enrollees. You want to be a candidate. 4. Attack every lever we already know about. Obicetrapib's mechanism tells us HDL-ApoE flux and Lp(a) matter for the APOE4 brain. We can't drop Lp(a) 46% without a drug, but we can raise HDL and protect ApoE function: aerobic exercise raises HDL; Mediterranean / MIND-pattern eating improves ApoE-mediated lipid handling; sleep fidelity protects glymphatic clearance; resistance training protects against vascular dementia. None of these individually matches obicetrapib's effect size. Collectively, started in your 50s, they move the needle. [link: APOE4 lifestyle protocol stack]